{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:29:49Z","timestamp":1789122589053,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1016\/j.jacl.2008.10.003","type":"journal-article","created":{"date-parts":[[2008,12,12]],"date-time":"2008-12-12T13:27:33Z","timestamp":1229088453000},"page":"436-446","source":"Crossref","is-referenced-by-count":14,"title":["Ezetimibe\/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non\u2013HDL-cholesterol, TC\/HDL-C, apolipoprotein B, apo-B\/apo-A-I, or C-reactive protein"],"prefix":"10.1016","volume":"2","author":[{"given":"Michael H.","family":"Davidson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Abate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Tershakovec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2008.10.003_bib1","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2008.10.003_bib2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2008.10.003_bib3","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.106.174516","article-title":"AHA\/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute","volume":"113","author":"Smith","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2008.10.003_bib4","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0828-282X(06)70310-5","article-title":"Canadian Cardiovascular Society position statement\u2014recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease","volume":"22","author":"McPherson","year":"2006","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacl.2008.10.003_bib5","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.atherosclerosis.2005.10.001","article-title":"The evolution of European guidelines: changing the management of cholesterol levels","volume":"185","author":"Erhardt","year":"2006","journal-title":"Atherosclerosis"},{"issue":"suppl 1","key":"10.1016\/j.jacl.2008.10.003_bib6","first-page":"S4","article-title":"Standards of medical care in diabetes\u20132006","volume":"29","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2008.10.003_bib7","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jacc.2006.04.070","article-title":"Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy","volume":"48","author":"Cannon","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"suppl","key":"10.1016\/j.jacl.2008.10.003_bib8","doi-asserted-by":"crossref","first-page":"34F","DOI":"10.1016\/j.amjcard.2005.06.010","article-title":"Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin","volume":"96","author":"Gotto","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2008.10.003_bib9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2008.10.003_bib10","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2008.10.003_bib11","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2008.10.003_bib12","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.amjcard.2005.04.019","article-title":"Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations","volume":"96","author":"Davidson","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2008.10.003_bib13","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1161\/01.ATV.0000245791.53245.ee","article-title":"NPC1L1: evolution from pharmacological target to physiological sterol transporter","volume":"26","author":"Huff","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2008.10.003_bib14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5551\/jat.14.99","article-title":"Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia","volume":"14","author":"Davis","year":"2007","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jacl.2008.10.003_bib15","doi-asserted-by":"crossref","first-page":"587","DOI":"10.4065\/80.5.587","article-title":"A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial","volume":"80","author":"Pearson","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacl.2008.10.003_bib16","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.clinthera.2004.11.016","volume":"26","author":"Bays","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.jacl.2008.10.003_bib17","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ahj.2004.11.023","article-title":"Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study","volume":"149","author":"Ballantyne","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2008.10.003_bib18","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1185\/030079906X132721","article-title":"Lipid-altering efficacy of the ezetimibe\/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients","volume":"22","author":"Catapano","year":"2006","journal-title":"Curr Med Res Opin"},{"issue":"suppl","key":"10.1016\/j.jacl.2008.10.003_bib19","doi-asserted-by":"crossref","first-page":"36K","DOI":"10.1016\/j.amjcard.2005.08.006","article-title":"Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B","volume":"96","author":"Stein","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2008.10.003_bib20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1520-037X.2005.4077.x","article-title":"Non-high-density lipoprotein cholesterol: why lower is better","volume":"8","author":"Garg","year":"2005","journal-title":"Prev Cardiol"},{"key":"10.1016\/j.jacl.2008.10.003_bib21","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1161\/01.CIR.0000038419.53000.D6","article-title":"Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy","volume":"106","author":"Grundy","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2008.10.003_bib22","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1365-2796.2006.01646.x","article-title":"Apolipoproteins AI and B as therapeutic targets","volume":"259","author":"Charlton-Menys","year":"2006","journal-title":"J Intern Med"},{"key":"10.1016\/j.jacl.2008.10.003_bib23","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.1995.03530100041032","article-title":"Identifying adults at increased risk of coronary disease","volume":"274","author":"Grover","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2008.10.003_bib24","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1001\/jama.294.3.326","article-title":"Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women","volume":"294","author":"Ridker","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2008.10.003_bib25","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0140-6736(01)07098-2","article-title":"High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study","volume":"358","author":"Walldius","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2008.10.003_bib26","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2008.10.003_bib27","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2008.10.003_bib28","first-page":"921","article-title":"Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update","volume":"169","author":"Genest","year":"2003","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.jacl.2008.10.003_bib29","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jacc.2008.04.052","volume":"52","author":"Ballantyne","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2008.10.003_bib30","doi-asserted-by":"crossref","first-page":"11i","DOI":"10.1016\/S0002-9149(02)02631-0","article-title":"Approach to lipoprotein management in 2001 National Cholesterol Guidelines","volume":"90","author":"Grundy","year":"2002","journal-title":"Am J Cardiol"},{"issue":"suppl","key":"10.1016\/j.jacl.2008.10.003_bib31","doi-asserted-by":"crossref","first-page":"3C","DOI":"10.1016\/j.amjcard.2004.02.006","article-title":"Emerging therapeutic strategies for the management of dyslipidemia in patients with the metabolic syndrome","volume":"93","author":"Davidson","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2008.10.003_bib32","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0272-2712(18)30645-0","article-title":"The Centers for Disease Control-National Heart, Lung and Blood Institute Lipid Standardization Program","volume":"9","author":"Myers","year":"1989","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.jacl.2008.10.003_bib33","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2337\/dc08-9018","article-title":"Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation","volume":"31","author":"Brunzell","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2008.10.003_bib34","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.atherosclerosissup.2005.02.005","article-title":"Markers of inflammation and their clinical significance","volume":"6","author":"Ballantyne","year":"2005","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.jacl.2008.10.003_bib35","article-title":"Pooled analysis of effects on C-reactve protein and low-density lipoprotein cholesterol in placebo-controlled tirals of ezetimbe monotherapy or ezetimibe added to baseline statin therapy","author":"Pearson","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2008.10.003_bib36","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/j.jacc.2007.01.083","article-title":"Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis","volume":"49","author":"Kinlay","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2008.10.003_bib37","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jacl.2008.02.002","article-title":"Effect of ezetimibe\/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic sndrome, or neither: Results of two subgroupa analysis","volume":"2","author":"Abate","year":"2008","journal-title":"J Clin Lipidol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287408008891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287408008891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T06:37:04Z","timestamp":1557988624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287408008891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S1933287408008891"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2008.10.003","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}